Takeda Pharmaceutical Co. Ltd. recently announced that it has partnered with the Chemo-Sero-Therapeutic Research Institute to distribute Kaketsuken’s seasonal influenza vaccine throughout Japan.
The new distributions will begin during the upcoming 2015-2016 influenza season. The Influenza A Vaccine “SEIKEN,” which is produced by Denka Seiken, will continue to be distributed by Takeda.
Seasonal influenza is most common during the early winter through the early spring season. The majority of people who contract seasonal influenza recover quickly, but for people with compromised immune systems, bronchitis, pneumonia and life-threatening severe complications can occur. The vaccine may protect people against influenza infections as well as suppress the most severe symptoms.
Because Japan’s Preventive Vaccination Law requires elderly people to receive routine vaccinations, the demand for these required vaccines is rising alongside the increasing number of aging people in Japan.
"We are pleased to have concluded a sales agreement on seasonal influenza vaccine with Kaketsuken,” Hitoshi Oinuma, head of the Japan Vaccine Business Unit of Takeda, said. “The agreement will bolster our supply of influenza vaccine and allow us to meet the demand of as many patients and medical professionals as possible. This agreement reinforces Takeda's commitment to public health in Japan."